Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C F Stewart

Showing results (71-80 of 91) with videos related to

Pageof 10
Sort By:
Blood|May 15, 1995
In vitro and in vivo activity of topotecan against human B-lineage acute lymphoblastic leukemia cellsF M Uckun, C F Stewart, G Reaman, et al.
Cancer Chemotherapy and Pharmacology|March 11, 1999
Relationship between tumor extracellular fluid exposure to topotecan and tumor response in human neuroblastoma xenograft and cell linesW C Zamboni, P J Houghton, J L Hulstein, et al.
Journal of Neuro-Oncology|August 17, 1999
Topotecan for the treatment of recurrent or progressive central nervous system tumors - a pediatric oncology group phase II studyR P Kadota, C F Stewart, M Horn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 10, 1999
Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenograftsJ Thompson, E O George, C A Poquette, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 2000
Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft modelsP J Houghton, C F Stewart, P J Cheshire, et al.
Investigational New Drugs|January 1, 1996
Topoisomerase I interactive drugs in children with cancerC F Stewart, W C Zamboni, W R Crom, et al.
Journal of the National Cancer Institute|April 16, 1998
Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenograftsW C Zamboni, C F Stewart, J Thompson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 31, 1998
A four-hour topotecan infusion achieves cytotoxic exposure throughout the neuraxis in the nonhuman primate model: implications for treatment of children with metastatic medulloblastomaW C Zamboni, A J Gajjar, T D Mandrell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2000
Pharmacokinetics of irinotecan and its metabolites SN-38 and APC in children with recurrent solid tumors after protracted low-dose irinotecanM K Ma, W C Zamboni, K M Radomski, et al.
CPT: Pharmacometrics & Systems Pharmacology|April 23, 2016
Translational Pharmacokinetic-Pharmacodynamic Modeling and Simulation: Optimizing 5-Fluorouracil Dosing in Children With Pediatric EpendymomaV M Daryani, Y T Patel, M Tagen, et al.
Pageof 10

Showing results (71-80 of 91) with videos related to

Sort By:
Pageof 10
Blood|May 15, 1995
In vitro and in vivo activity of topotecan against human B-lineage acute lymphoblastic leukemia cellsF M Uckun, C F Stewart, G Reaman, et al.
Cancer Chemotherapy and Pharmacology|March 11, 1999
Relationship between tumor extracellular fluid exposure to topotecan and tumor response in human neuroblastoma xenograft and cell linesW C Zamboni, P J Houghton, J L Hulstein, et al.
Journal of Neuro-Oncology|August 17, 1999
Topotecan for the treatment of recurrent or progressive central nervous system tumors - a pediatric oncology group phase II studyR P Kadota, C F Stewart, M Horn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 10, 1999
Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenograftsJ Thompson, E O George, C A Poquette, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 2000
Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft modelsP J Houghton, C F Stewart, P J Cheshire, et al.
Investigational New Drugs|January 1, 1996
Topoisomerase I interactive drugs in children with cancerC F Stewart, W C Zamboni, W R Crom, et al.
Journal of the National Cancer Institute|April 16, 1998
Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenograftsW C Zamboni, C F Stewart, J Thompson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 31, 1998
A four-hour topotecan infusion achieves cytotoxic exposure throughout the neuraxis in the nonhuman primate model: implications for treatment of children with metastatic medulloblastomaW C Zamboni, A J Gajjar, T D Mandrell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2000
Pharmacokinetics of irinotecan and its metabolites SN-38 and APC in children with recurrent solid tumors after protracted low-dose irinotecanM K Ma, W C Zamboni, K M Radomski, et al.
CPT: Pharmacometrics & Systems Pharmacology|April 23, 2016
Translational Pharmacokinetic-Pharmacodynamic Modeling and Simulation: Optimizing 5-Fluorouracil Dosing in Children With Pediatric EpendymomaV M Daryani, Y T Patel, M Tagen, et al.
Pageof 10